Navigation Links
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Date:3/10/2008

company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning (i) the safety of the company's rHuPH20 enzyme and (ii) any impact on the regulatory applications for any third-party) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. Th
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
2. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
3. Halozyme Therapeutics Amends Stockholder Rights Plan
4. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
5. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
6. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
7. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
8. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. ExonHit Therapeutics - 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Canada (PRWEB) July 30, 2014 ... available in health services research for a relatively ... upswing in interest regarding the use of these ... practice conditions. , By combining today’s powerful computer ... the digital era, ‘big data’ holds significant promise ...
(Date:7/30/2014)... Sales Horizons, a leader in sales training programs, ... for companies engaged in complex B2B sales. , Created ... salespeople over 25 years in market-leading Fortune 500 companies, ... to address the unique sales challenges of companies in ... consists of two parts: Mastering the Complex Sale, ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... Novavax, Inc. (Nasdaq: NVAX ) today announced that ... a press release to be issued after 8:00 a.m. Eastern ... investor conference call to discuss its financial results at 10:00 ... be hosted by Novavax President and Chief Executive Officer Dr. ...
... a business initiative of W.L. Gore & Associates, announced ... a new production facility in Elkton, MD. The ... Gore PharmBIO,s products and was needed in order to ... key feature of the new facility is a state-of-the-art-cleanroom. ...
... March 17 PharmaNet Development Group, Inc. (the ... PDGI ), a leading provider of clinical development ... medical device companies, announced that, pursuant to the ... 2.25% convertible senior notes due 2024 (the "Convertible ...
Cached Biology Technology:Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3Gore PharmBIO Products Opens New Facility with State-of-the-Art-Cleanroom Facility Built to Support Demand for Growing STA-PURE(TM) Product Line 2Gore PharmBIO Products Opens New Facility with State-of-the-Art-Cleanroom Facility Built to Support Demand for Growing STA-PURE(TM) Product Line 3PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 2PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 3PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 4PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 5PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 6PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes 7
(Date:7/30/2014)... the Entomological Society of America (ESA) has elected ten ... as a Fellow acknowledges outstanding contributions to entomology in ... or administration. The following Fellows will be recognized during ... will be held November 16-19, 2014 in Portland, Oregon. ... professor with the Department of Plant, Soil and Entomological ...
(Date:7/30/2014)... The Jackson Laboratory has received a pledge of $1 ... and name the Laboratory,s new Neurobehavioral Biometry Center. ... Biometry Center will enable the Laboratory to develop a ... with the ultimate goal of accelerating the pace of ... will serve as a premier resource for the Laboratory ...
(Date:7/30/2014)... changing climate threaten some of the world,s most ... establish seed collections to save the seeds in ... some genetic diversity., For decades, these seed collections ... a one-size-fits-all approach for how many seeds to ... regardless of species, pollination mode, growth habitat and ...
Breaking Biology News(10 mins):Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Saving seeds the right way can save the world's plants 2
... used raw materials in butanol production have so far ... the starting point in the Aalto University study was ... which does not compete with food production. ... successfully combine modern pulp - and biotechnology. Finland,s advanced ...
... Shenzhen, China Inner Mongolia Agricultural University (IMAU), ... BGI, the world,s largest genomics organization, jointly announced ... genomic study will help researchers to better understand ... their ancestors from Africa to Asia, which also ...
... has been explained for the first time, opening the ... are at high risk of developing fatal bacterial infections, ... due to generalised immunosuppression by malaria, whereby the entire ... at the London School of Hygiene & Tropical Medicine ...
Cached Biology News:Chemicals and biofuel from wood biomass 2Chinese scientists announce the first complete sequencing of Mongolian genome 2Immunological defense mechanism leaves malaria patients vulnerable to deadly infection 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: